Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10530234 | 1.00 | KDM4E (0.33) | KDM4EGAAPOLBTDP1HPGD | |
| SCHEMBL13276440 | 1.00 | KDM4E (0.33) | KDM4EGAAPOLBTDP1HPGD | |
| SCHEMBL60409 | 1.00 | KDM4E (0.33) | KDM4EGAAPOLBTDP1HPGD | |
| SCHEMBL6245109 | 1.00 | KDM4E (0.33) | KDM4EGAAPOLBTDP1HPGD | |
| SCHEMBL3225586 | 0.96 | — | — | |
| SCHEMBL10796699 | 0.90 | GAA (0.31) | GAAPOLBTDP1 | |
| SCHEMBL16161480 | 0.90 | GAA (0.31) | GAAPOLBTDP1 | |
| SCHEMBL2113593 | 0.90 | GAA (0.31) | GAAPOLBTDP1 | |
| SCHEMBL8909769 | 0.90 | GAA (0.31) | GAAPOLBTDP1 | |
| SCHEMBL19293544 | 0.90 | GAA (0.31) | GAAPOLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192279-A1 | Pyridazinones as antagonists of alpha4 integrins | JANSSEN PHARAMACEUTICA, N.V. (BE) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192279-A1 | Pyridazinones as antagonists of alpha4 integrins | ITGB4, ITGA4, ITGB5 | KDM4E 1762/4885GAA 2720/4885POLB 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.